MGA (Megestrol Acetate) is a prescription medication utilized to support the management of certain clinical concerns by providing symptomatic relief. Its main therapeutic applications are focused on two distinct areas: the management of serious, unexplained weight loss and the palliative care of specific malignancies.

In the context of wasting syndromes, MGA is indicated to help address anorexia (loss of appetite) and cachexia (muscle wasting) in patients, which commonly occurs with chronic illness. The expected benefit is the promotion of appetite and support for weight stabilization. Additionally, MGA may be used in the palliative management of hormone-sensitive malignancies, specifically endometrial cancer and advanced breast cancer.

“The goal of MGA use is to offer supportive care and assist patients in maintaining body weight and improving overall comfort during treatment.”

Quick Fact: Relief for Wasting Syndromes and Hormone-Sensitive Cancers

Eligibility: Who Can and Cannot Use Megestrol Acetate (MGA)?

Official regulatory documentation strictly defines the patient populations eligible for Megestrol Acetate therapy. Use is primarily established for adult patients requiring treatment for the approved indications. Eligibility is subject to several exclusions and restrictions documented in the product labeling.

Eligibility Classification	Regulatory Rule
Absolute Contraindications	Known or suspected pregnancy (Risk of fetal harm). Hypersensitivity to Megestrol Acetate or any component of the formulation.
Age-Related Restrictions	Pediatric patients are generally not recommended to use MGA, as safety and effectiveness have not been established. Geriatric use requires caution due to the greater frequency of decreased organ function.
Conditional Use/Caution	Caution is advised for patients with a history of thromboembolic disease, impaired renal function, or impaired hepatic function. Patients with pre-existing diabetes mellitus must be monitored closely for potential exacerbation.
Reproductive Status	Women of childbearing potential are required to use effective contraception during and following treatment. Nursing mothers are advised to discontinue breastfeeding.

Eligibility for MGA is formally dependent on the adult patient status and the absence of absolute contraindications, with conditional use rules applying to specific organ impairment and pre-existing medical conditions as documented by regulatory authorities.

MGA Interactions with other medicines and products

The interaction profile for Melengestrol Acetate (MGA) is defined by its regulatory status as a specialized veterinary medicated feed additive. Official government regulatory documents focus on mandated co-administration rules and hormonal incompatibility rather than typical metabolic or transporter-based interactions found in human medicines. No pharmacokinetic interactions that alter MGA clearance or exposure (e.g., via CYP enzymes) are formally documented in regulatory labels.

Regulatory Interaction Classifications

Classification	Interacting Agents
Contraindicated Combination	Other hormone drugs
Approved Combinations	Monensin, Tylosin, Lasalocid, Ractopamine, Oxytetracycline

Official Restrictions and Constraints

The most significant interaction constraint is the explicit prohibition of co-administration with other hormone drugs. This establishes a regulatory boundary to prevent unintended hormonal effects. Conversely, the regulatory process officially approves and requires the co-administration of MGA with specific non-hormone agents, such as the anticoccidial Monensin and the antimicrobial Tylosin, when used as a feed additive for certain purposes. As MGA is administered with the animal's complete ration, its use is inherently constrained by the administration method as a medicated feed, with no required timing separation from other substances.

How MGA Works

Megestrol Acetate (MGA) exerts its effects through several distinct pharmacodynamic pathways, primarily involving steroid hormone receptor interactions and metabolic modulation.

---

Progestin Receptor Agonism

MGA acts as an agonist of the Progesterone Receptor (PR), engaging mechanisms that typically regulate reproductive and endocrine processes. This receptor-mediated signaling leads to downstream effects that influence the hypothalamic-pituitary-gonadal axis, such as antigonadotropic activity, resulting in altered hormonal feedback regulation.

---

Glucocorticoid Receptor Modulation

The drug also possesses glucocorticoid activity, acting as a partial agonist at the Glucocorticoid Receptor (GR). This engagement with the glucocorticoid signaling cascade is relevant in systems that regulate stress and inflammatory responses, resulting in the modulation of GR-dependent gene expression and influencing glucocorticoid-related metabolic and inflammatory cascades.

---

Unidentified Metabolic and Appetite Effects

MGA is thought to modulate key pathways associated with appetite regulation and metabolism, though the precise molecular targets remain unknown. This effect is independent of its primary hormonal actions and influences signaling pathways related to energy balance and nutrient processing, affecting physiological regulation of these processes and leading to altered physiological parameters associated with the drug's activity.

How MGA is Used: Official Administration Guidelines

The use of Melengestrol Acetate (MGA) is strictly defined by guidelines for administration as a veterinary feed additive. The official instructions dictate the preparation, delivery route, and duration of use, which must be followed precisely to adhere to the product's authorized protocol.

Administration Route and Dose

Melengestrol acetate is administered solely via the oral route, integrated into the animal's daily feed as a Type C Medicated Feed. The dosing is specific and continuous:

Animal Purpose	Daily Dose Regimen (Per Head Per Day)
Heifers for Slaughter	0.25 to 0.5 mg
Heifers for Breeding	0.5 mg

Frequency and Duration

The medicine must be fed once daily and continuously. The treatment duration is strictly dependent on the animal's purpose:

• Slaughter Heifers: MGA is fed for the final 28 to 42 days on feed.
• Breeding Heifers: Feeding must not exceed 24 days.

Preparation and Restrictions

Official instructions require the MGA to be thoroughly mixed into the final feed. For liquid feeds, mandatory agitation or recirculation is required for at least 10 minutes prior to use and daily thereafter. Use is limited to heifers (unspayed female cattle) and is not for use in pre-ruminating calves.

Research Evidence / Overview of Studies for Melengestrol Acetate (MGA)

---

Evidence for Use in Reproductive Cycle Control (Estrus Synchronization)

The application of Melengestrol acetate (MGA) was primarily studied in research exploring the reproductive cycle in livestock. Research focused on this application was evaluated in Randomized Controlled Trials (RCTs) and Controlled Field Trials, primarily involving cattle (heifers) and sheep (ewes). These studies monitored outcomes such as the rate of estrous expression, ovulation, and the measured pregnancy or conception rates. Trials described patterns observed in reproductive timing, though variability in findings was noted, often depending on co-administered hormones or management practices.

Evidence for Use in Growth Promotion and Feed Efficiency

MGA was studied for a second context: as a feed additive that research examined for growth promotion. Research in this area was evaluated in Controlled Feeding Trials and large-scale observational settings involving beef heifers. The research examined specific outcomes including the rate of weight gain and calculations of Feed Conversion Efficiency, which is used to monitor the relationship between feed intake and weight change. The data show patterns related to weight accumulation, reflecting the specific conditions under which the studies were conducted. Research concerning the direct biological processes by which the compound can influence weight gain remains confined to laboratory study models.

---

Duration of Study Follow-up and Remaining Uncertainty

The majority of studies examining MGA were conducted during defined, short-to-intermediate time intervals. The evidence base reports limited information that tracks animals over their full lifespan or across multiple cycles, meaning the long-term effects are not fully established. Research also highlights what is known — and what is still uncertain regarding specialized use. The evidence quality varies across studies conducted in different captive animal species, and data for certain groups remain insufficient to draw broad conclusions. Key limitations include comparative evidence being lacking against all other management techniques.

Key Studies & References

1. FREEDOM OF INFORMATION SUMMARY ANADA 200-805: MEL™ 500 (melengestrol acetate Type A liquid medicated article)

Common questions about MGA (FAQ)

Q: Does MGA have any effect on appetite or weight gain?

A: Official product information states that Melengestrol Acetate (MGA) is indicated and approved for specific uses in livestock, including an increased rate of weight gain and improved feed efficiency. These effects are part of the drug's approved indications when administered in feed to heifers being raised for slaughter.

Q: What happens when MGA is stopped?

A: Regulatory labels advise against withdrawal periods of three to five days or more for heifers being fed for slaughter, to prevent the animals from entering estrus (or 'heat') at the time of loading. Regulatory warnings also indicate that a reduced conception rate may occur if breeding is attempted within a specific timeframe (1 to 12 days) following the cessation of the drug in breeding animals.

Q: What kind of doctor or specialist prescribes MGA?

A: Melengestrol Acetate is classified as a veterinary drug. Its administration is regulated, and for certain uses, it requires supervision or an order from a licensed veterinarian, particularly when it is administered in a medicated feed.

Q: Is there a withdrawal period required before an animal can be sent to slaughter?

A: Official information advises against withdrawal periods of three to five days or more to prevent unwanted reproductive effects. However, at least one regulatory agency instructs that the medicated feed should be discontinued at least 24 hours before slaughter. This timing constraint is put in place to comply with official human food safety regulations.

Q: What happens if a pre-ruminating calf accidentally ingests MGA?

A: Official warnings state that Melengestrol Acetate is explicitly not for use in pre-ruminating calves. This restriction is based on the fact that residue withdrawal times, which are required for food safety purposes, have not been officially established for this young animal population.

Q: Can MGA be used for weight gain in humans?

A: No, the official product label for Melengestrol Acetate (MGA) carries a strict regulatory warning that the product is NOT FOR HUMAN USE. It is exclusively formulated and approved as a specialized veterinary drug.

Q: How should I dispose of MGA liquid feed?

A: Regulatory safety documents advise that all waste, including liquid feed, must be managed in accordance with local, state, and federal regulations. General guidance advises taking precautions to prevent the substance from entering drains or water courses, due to the drug's potential effects on aquatic organisms.

Q: What are the known long-term side effects of MGA?

A: Regulatory documents and evaluations primarily focus on the effects observed during the approved, short-term feeding periods. The official labels and summaries do not explicitly quantify or list long-term side effects that extend over the full lifespan of the animal population.

Medrogestone Acetate (MGA) should be stored correctly to maintain its effectiveness and safety. Keep the medicine in its original container, tightly closed, and out of the reach of children and pets. It should be stored at room temperature, away from excess heat and moisture. Avoid storing it in the bathroom or near the kitchen sink.

---

Disposal Method	Guidance
Ideal Method	Utilize a community drug take-back program or a DEA-authorized disposal location, which are the safest ways to discard expired or unwanted medicine.
Alternative Method	If a take-back program is unavailable, consult the drug's patient information leaflet for specific guidance. Do not flush MGA down the toilet or pour it down a drain unless explicitly instructed to do so.

---

To dispose of medication at home, mix it with an unappealing substance like dirt or used coffee grounds, place the mixture in a sealed plastic bag, and then discard it in your trash. Remove or obscure all personal identification on the container before disposal. These precautions prevent accidental ingestion or misuse.